NCT03056209 - Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 26, 2017

Primary Completion Date

April 16, 2018

Study Completion Date

April 16, 2018

Conditions

MELAS SyndromeMitochondrial Respiratory Chain Deficiencies

Interventions

DRUG

KL1333 25 mg

oral administration, single dose, 25 mg 1 tab

DRUG

KL1333 50 mg

oral administration, single dose, 25 mg 2 tabs

DRUG

KL1333 100 mg

oral administration, single dose, 100 mg 1 tab

DRUG

KL1333 200 mg

oral administration, single dose, 100 mg 2 tabs

DRUG

KL1333 400 mg

oral administration, single dose, 100 mg 4 tabs

DRUG

KL1333 600 mg

oral administration, single dose, 100 mg 6 tabs

DRUG

KL1333 800 mg

oral administration, single dose, 100 mg 8 tabs

DRUG

Placebo

oral administration, placebo

Trial Locations (1)

Seoul National University Hospital, Seoul

All Listed Sponsors

lead

Yungjin Pharm. Co., Ltd.

INDUSTRY